Oragenics climbs as COVID-19 spike protein produces antibodies in mice

Oragenics

30/08/2021 14:49

** Shares of drug developer  OGEN.A  rise 8.6% to 74 cents,
trading above their 50-day moving avg price
    ** OGEN says its COVID-19 spike protein, produced with its
Canadian partner's platform generates neutralizing antibodies in
mice, when administered with other adjuvants  urn:newsml:reuters.com:*:nBw6XRssga
    ** OGEN in July entered licensing agreement with National
Research Council of Canada for tech, which could help co to
design and develop next-gen COVID-19 vaccines  urn:newsml:reuters.com:*:nL4N2P32S3
    ** Co says platform will speed up study of vaccine
candidates; hamster study to begin at the end of Aug
    ** Expects to file an application with U.S. FDA to start
trials in humans in Q1 2022
    ** Co's lead product is Terra CoV-2, a vaccine candidate to
prevent COVID-19
    ** OGEN had risen 51.7% YTD, up to the last close 

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))